Yubo International Biotech Limited
YBGJ · OTC
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -96.7% | -91.6% | -8.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -6,031% | 50.5% | 65.9% | 91.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -51,006.3% | -1,155.7% | -124% | -52.6% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -51,161.5% | -1,155.3% | -123.9% | -52.6% |
| EPS | -0.015 | -0.01 | -0.013 | -0.006 |
| % Growth | -46.5% | 22.9% | -118.3% | – |
| EPS Diluted | -0.015 | -0.01 | -0.013 | -0.006 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -51,831.2% | -1,129.3% | -122.3% | -51.6% |